Gracell Biotechnologies Operating Income 2011-2025 | GRCL

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Gracell Biotechnologies

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-464 M	-214 M	-147 M	-62.5 M	-	-	-	-	-	-	-

All numbers in CNY currency

Indicator range from annual reports

Maximum	Minimum	Average
-62.5 M	-464 M	-222 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	-78.1 M	$ 4.93	4.78 %	$ 818 M	Canada
Aclaris Therapeutics ACRS	-142 M	$ 3.2	-1.69 %	$ 247 M	USA
AlloVir ALVR	-65.4 M	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	-24.6 M	$ 1.07	-5.75 %	$ 295 K	USA
Ascendis Pharma A/S ASND	-452 M	$ 213.33	-3.22 %	$ 5 B	Danmark
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
BioVie BIVI	-18.1 M	$ 1.42	-1.85 %	$ 2.1 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-140 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	15.3 B	$ 93.93	-0.93 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	-209 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	-58.1 M	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	-33.3 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	205 M	$ 26.45	4.67 %	$ 1.28 B	USA
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	-87.6 M	$ 9.6	0.37 %	$ 141 M	USA
Can-Fite BioPharma Ltd. CANF	-8.13 M	$ 0.26	-6.98 %	$ 566 M	Israel
Catalyst Biosciences CBIO	-67.2 M	$ 12.98	-7.91 %	$ 854 M	USA
Arena Pharmaceuticals ARNA	-624 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	-87.1 M	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	10.2 M	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	58.5 M	$ 548.58	-2.78 %	$ 41.6 B	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-7.83 M	$ 2.37	2.83 %	$ 14.9 M	USA
AstraZeneca PLC AZN	1.06 B	$ 91.59	1.95 %	$ 96.9 B	Britain
Celldex Therapeutics CLDX	-195 M	$ 27.09	-1.53 %	$ 1.74 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	-6.36 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	242 M	$ 8.97	-0.44 %	$ 1.45 B	Britain
BeiGene, Ltd. BGNE	-568 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-704 M	$ 11.33	-1.78 %	$ 733 M	USA
Biogen BIIB	7.04 B	$ 175.2	0.63 %	$ 25.5 B	USA
Abeona Therapeutics ABEO	-47.1 M	$ 5.07	-5.5 %	$ 108 M	USA
Corcept Therapeutics Incorporated CORT	137 M	$ 87.67	-0.36 %	$ 9.05 B	USA
ADiTx Therapeutics ADTX	-27.9 M	$ 1.43	-36.18 %	$ 18.8 K	USA
Cellectar Biosciences CLRB	-39 M	$ 3.28	-9.39 %	$ 40.1 M	USA
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-98.1 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Catalyst Pharmaceuticals CPRX	195 M	$ 24.29	2.84 %	$ 2.88 B	USA